Addition of danoprevir to hepatitis C treatments shown to improve results
Research showed that the addition of danoprevir to treatments reduced levels of hepatitis C in patients in less than one week. In addition, 85 percent of patients had no detectable amounts of the virus after six months of treatment.
Danoprevir was developed as a highly-selective and potent macrocyclic protease inhibitor of the hepatitis C virus.
"Despite recent advances, the current hepatitis C treatment regimen is burdensome on the patient and prone to adverse events," Professor of Hepatology at the University of Paris Dr. Patrick Marcellin said. "The promising results from this study offer hope that danoprevir can improve the quality of life for patients suffering from this disease."
Seventy-nine percent of patients who had danorevir added to their treatments were able to shorten their hepatitis treatments, which is an important development since treatments can have an adverse affect a patient's health.
Danoprevir's impact on hepatitis C treatment has been vetted in phase two randomized, placebo-controlled studies. Additional studies are underway to determine if the drug can maintain its effectiveness in the treatment of hepatitis C at lower dosages.